Literature DB >> 15695822

Src kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear factor-kappaB.

Donald L Courter1, Lucy Lomas, Marta Scatena, Cecilia M Giachelli.   

Abstract

Integrin adhesion to extracellular matrix proteins protects adhesion-dependent cells from suspension-induced apoptosis. Previous studies indicate that activation of the transcription factor nuclear factor-kappaB was necessary for the integrin alpha(v)beta3 ligand osteopontin to protect endothelial cells from apoptosis caused by serum withdrawal. In this study, beta3 integrins were overexpressed in smooth muscle cells. When plated on osteopontin, cells overexpressing wild-type beta3 had enhanced cell adhesion, cell spreading, and nuclear factor-kappaB activation compared with vector control. Removal of four amino acids (759X) from the C terminus of beta3 eliminated the ability of the integrin to promote these processes. Single amino acid substitutions indicated that phosphorylation at tyrosine 759 was not required for activation of the transcription factor, however this residue appeared to play a structural role, because mutation to alanine significantly inhibited nuclear factor-kappaB activation. The Src family of tyrosine kinases represents important transducers during integrin signaling, and the C terminus of beta3 has been implicated as the binding site for Src. Immunoprecipitations demonstrated that Src associated with wild-type beta3 integrins, but Src and integrins lacking the C terminus (759X) did not form a complex. Pharmacological inhibition with the Src inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) or overexpression of kinase-dead c-Src blocked nuclear factor-kappaB activation. Mouse embryonic fibroblasts deficient for Src failed to activate nuclear factor-kappaB when plated on osteopontin, in contrast to control fibroblasts. Together, these experiments indicate that the C terminus of beta3 and Src activity are required for integrin alpha(v)beta3-mediated nuclear factor-kappaB activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695822     DOI: 10.1074/jbc.M412555200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Analysis of Fyn function in hemostasis and alphaIIbbeta3-integrin signaling.

Authors:  Kumar B Reddy; Dawn M Smith; Edward F Plow
Journal:  J Cell Sci       Date:  2008-04-22       Impact factor: 5.285

2.  Skeletal loading regulates breast cancer-associated osteolysis in a loading intensity-dependent fashion.

Authors:  Yao Fan; Aydin Jalali; Andy Chen; Xinyu Zhao; Shengzhi Liu; Meghana Teli; Yunxia Guo; Fangjia Li; Junrui Li; Amanda Siegel; Lianxiang Yang; Jing Liu; Sungsoo Na; Mangilal Agarwal; Alexander G Robling; Harikrishna Nakshatri; Bai-Yan Li; Hiroki Yokota
Journal:  Bone Res       Date:  2020-02-14       Impact factor: 13.567

Review 3.  Tumor-stromal interactions in pancreatic cancer.

Authors:  Clifford Whatcott; Haiyong Han; Richard G Posner; Daniel D Von Hoff
Journal:  Crit Rev Oncog       Date:  2013

Review 4.  Integrins in cancer: biological implications and therapeutic opportunities.

Authors:  Jay S Desgrosellier; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

5.  VEGF modulates NMDA receptors activity in cerebellar granule cells through Src-family kinases before synapse formation.

Authors:  Claire Meissirel; Carmen Ruiz de Almodovar; Ellen Knevels; Cathy Coulon; Naura Chounlamountri; Inmaculada Segura; Pierre de Rossi; Stefan Vinckier; Kristof Anthonis; Bérangère Deléglise; Maria de Mol; Carine Ali; Karel Dassonville; Ellen Loyens; Jérôme Honnorat; Yvette Michotte; Véronique Rogemond; Ilse Smolders; Thomas Voets; Denis Vivien; Pieter Vanden Berghe; Ludo Van den Bosch; Wim Robberecht; Alain Chédotal; Salvatore Oliviero; Mieke Dewerchin; Dietmar Schmucker; Nicole Thomasset; Paul Salin; Peter Carmeliet
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-29       Impact factor: 11.205

6.  Lack of beta3 integrin signaling contributes to calpain-mediated myocardial cell loss in pressure-overloaded myocardium.

Authors:  Geetha Suryakumar; Harinath Kasiganesan; Sundaravadivel Balasubramanian; Dhandapani Kuppuswamy
Journal:  J Cardiovasc Pharmacol       Date:  2010-06       Impact factor: 3.105

7.  The integrin alpha2beta1 agonist, aggretin, promotes proliferation and migration of VSMC through NF-kB translocation and PDGF production.

Authors:  Ching-Hu Chung; Kuan-Ting Lin; Chien-Hsin Chang; Hui-Chin Peng; Tur-Fu Huang
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

8.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

9.  Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels.

Authors:  Sudhakar Kalakonda; Shreeram C Nallar; Ping Gong; Daniel J Lindner; Simeon E Goldblum; Sekhar P Reddy; Dhananjaya V Kalvakolanu
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

10.  Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies.

Authors:  David A Reardon; David Cheresh
Journal:  Genes Cancer       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.